Comparative <i>in vitro</i>
 activity of carbapenems against clinical isolates of <i>Acinetobacter baumannii</i>

Douraghi, Masoumeh; Ghalavand, Zohreh; Rostami, Mahmoud Nateghi; Zeraati, Hojjat; Aliramezani, Amir; Rahbar, Mohammad; Mohammadzadeh, Mona; Ghourchian, Sedighe; Boroumand, MA; Abdollahi, Alireza

doi:10.1111/jam.13178

Cited by 3 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, doripenem was comparable to other carbapenems, including imipenem and meropenem, in terms of microbiological eradication rate in the subgroup analysis. All these findings may be well explained by previous in vitro studies [3,4,19,20,21] that showed doripenem had a greater or similar in vitro activity against bacteria, including multi-drug resistant organisms. In this meta-analysis, we did not assess we did not evaluate the association between in vitro activity and the in vivo response of different organisms, especially for antibiotic-resistant pathogens, because the associated information was limited.…”

Section: Discussionsupporting

confidence: 53%

“…Carbapenems, including imipenem and meropenem, remain the mainstay of treatment for hospital-acquired infections, especially for the multidrug-resistant organism associated infections [1]. Doripenem is another important carbapenem, and has excellent bactericidal activity against most nosocomial pathogens according to several in vitro studies [2,3,4,5]. A global surveillance showed that doripenem was at least two-fold more potent in in vitro activities than imipenem and meropenem against Pseudomonas aeruginosa —an important nosocomial pathogen [3].…”

Section: Introductionmentioning

confidence: 99%

“…A global surveillance showed that doripenem was at least two-fold more potent in in vitro activities than imipenem and meropenem against Pseudomonas aeruginosa —an important nosocomial pathogen [3]. For another notorious pathogen— Acinetobacter baumannii , doripenem displayed comparable in vitro activities to imipenem and meropenem [4]. Clinically, doripenem is approved for the treatment of patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and pyelonephritis, and healthcare-associated pneumonia (HAP) including ventilator-associated pneumonia (VAP) in Europe and in other countries, other than United States.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials

Lai

Cheng

Chen

et al. 2019

JCM

View full text Add to dashboard Cite

This study aims to assess the efficacy and safety of doripenem on treating patients with acute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April 2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment of acute bacterial infection were included. The primary outcome was the clinical success rate and the secondary outcomes were microbiological eradication rate and risk of adverse events. Eight randomized controlled trials (RCTs) were included. Overall, doripenem had a similar clinical success rate with comparators (odds ratio [OR], 1.15; 95% CI, 0.79–1.66, I2 = 58%). Similar clinical success rates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46–1.53, I2 = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57–1.72). For complicated urinary tract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95% CI, 1.13–3.17, I2 = 0%). The pool analysis comparing doripenem and other carbapenems showed no significant differences between each other (OR, 0.96, 95% CI, 0.59–1.58, I2 = 63%). Doripenem also had a similar microbiological eradication rate with comparators (OR, 1.08; 95% CI, 0.86–1.36, I2 = 0%). Finally, doripenem had a similar risk of treatment-emergent adverse events as comparators (OR, 0.98; 95% CI, 0.83–1.17, I2 = 33%). In conclusion, the clinical efficacy of doripenem is as high as that of the comparator drugs in the treatment of acute bacterial infection; furthermore, this antibiotic is as well tolerated as the comparators.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials

Lai

Cheng

Chen

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Screening of resistance to a carbapenem according to the disk diffusion method was common among the studies. 8 – 23 Although this method may be applicable for many antimicrobials, however, for carbapenems more confirmatory tests beyond the disk diffusion assay are needed. In this setting, MIC would help for detection of resistant isolates.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies were multicenter, 8 – 12 but the sample sizes for three of them were small. 10 , 13 , 14 The trend of resistance to a carbapenem did not follow a specific pattern.…”

Section: Resultsmentioning

confidence: 99%

The threat of carbapenem-resistant gram-negative bacteria in a Middle East region

Davoudi-Monfared¹,

Khalili²

2018

IDR

View full text Add to dashboard Cite

Data on the status of carbapenem-resistant microorganisms in the Middle East countries are scarce. The aim of this review was to collect available data regarding resistance to carbapenems in a Middle East region. Available data regarding carbapenem-resistant isolates were considered for evaluation in this review. Biomedical electronic databases were systematically searched to find related articles. The key terms used were “carbapenem-resistant, resistant gram-negative bacilli, Enterobacteriaceae, fermenting and non-fermenting gram-negative bacilli, Pseudomonas, Acinetobacter, Klebsiella and Iran”. After primary screening, 275 relevant articles were selected to be assessed thoroughly. Resistance rate to carbapenems was reported between 1% and 86% during years 2006–2018. Most of the carbapenem-resistant microorganisms were isolated from burn patients. Modified Hodge test was a commonly used phenotypic test. Only in few studies, genotypic assays were considered. Pattern of antibiotic use can affect emergence of resistant microorganisms. Rational use of drugs, and specifically, antibiotics is a challenging issue in developing countries. Mean number of drugs per prescription in these countries was higher than the World Health Organization standards. Overuse of antibiotics, especially injectable ones, and easy access to antibiotics without prescription is a warning alarm for future antibiotic resistance in developing countries. Establishing antimicrobial stewardship’s programs is new in the hospitals. Unfortunately, rules and regulatory issues to restrict antibiotic access in community pharmacies and prescription by general physicians are limited.

show abstract

Occurrence of carbapenem-resistant organisms in gastrointestinal postoperative infections: A therapeutic challenge

Rupert¹,

Sankar

Govindaraj³

et al. 2021

IJMR

View full text Add to dashboard Cite

Dissemination of multidrug resistant organisms including Carbapenem-Resistant Organisms (CRO) in Hospitals is of global concern. Such nosocomial infections are more common during surgical procedures involving prolonged post-operative care and Hospital stay. Treatment options include administration of prophylactic antibiotics, which are broad-spectrum antibiotics. However, long-term administration of these antibiotics leads to an increase in the incidence of multidrug resistant organisms in Hospital sectors. To evaluate early detection of carbapenemase producing organisms from the clinical isolates of postoperative patients by carba NP test. The study was conducted at the diagnostic laboratory in clinical samples obtained from hospitalized patients. A total of 716 clinical samples were tested by employing basic microbiological and biochemical testing methods and the isolates were screened for antimicrobial susceptibility. Carbapenem-resistant isolates were then confirmed by E-test (imipenem, meropenem) and also via carba NP test.In a total of 716 samples, 257 tested positive for various microorganisms, of which 230 gram-negative bacilli were identified. Amongst them, 93 isolates were identified as resistant to carbapenem by disc diffusion method of which 50 isolates were tested for carbapenemase production. Within the 50 isolates, 47 isolates were resistant to E-test meropenem and 40 isolates were resistant to imipenem. Of note, 35 out of the 50 CROs were identified as carbapenemase producers. Our results show that Carba NP test is a simple method that can be employed routinely for early detection of carbapenemase mediated CROs thus reducing the spread of resistant strains in Hospitals.

show abstract

Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii

Abstract: Doripenem should be considered as a therapeutic option for monotherapy or combination therapy, particularly when the therapeutic options are limited.

Cited by 3 publications

References 25 publications

The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials

The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials

The threat of carbapenem-resistant gram-negative bacteria in a Middle East region

Occurrence of carbapenem-resistant organisms in gastrointestinal postoperative infections: A therapeutic challenge

Contact Info

Product

Resources

About